Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1126/sciadv.abh3032 http://scihub22266oqcxt.onion/10.1126/sciadv.abh3032 34193418!8245040!34193418     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Adv 2021 ; 7 (27): ä Nephropedia Template TP {{tp|p=34193418|t=2021. Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies |pdf=|usr=}}{{34193418}} gab.com Text Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies JO: Sci Adv http://www.kidney.de/pget.php?&tw=1&pmid=34193418 #FOAvip The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates the rapid development of new therapies against coronavirus disease 2019 (COVID-19) infection. Here, we present the identification of 200 approved drugs, appropriate for repurposing against COVID-19. We constructed a SARS-CoV-2-induced protein network, based on disease signatures defined by COVID-19 multiomics datasets, and cross-examined these pathways against approved drugs. This analysis identified 200 drugs predicted to target SARS-CoV-2-induced pathways, 40 of which are already in COVID-19 clinical trials, testifying to the validity of the approach. Using artificial neural network analysis, we classified these 200 drugs into nine distinct pathways, within two overarching mechanisms of action (MoAs): viral replication (126) and immune response (74). Two drugs (proguanil and sulfasalazine) implicated in viral replication were shown to inhibit replication in cell assays. This unbiased and validated analysis opens new avenues for the rapid repurposing of approved drugs into clinical trials. Twit Text FOAVip Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies ????Sci Adv http://www.kidney.de/pget.php?&tw=1&pmid=34193418 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34193418 #FOAvip English Wikipedia <ref>{{Cite pmid|34193418}}</ref> Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies #MMPMID34193418 Han N; Hwang W; Tzelepis K; Schmerer P; Yankova E; MacMahon M; Lei W; M Katritsis N; Liu A; Felgenhauer U; Schuldt A; Harris R; Chapman K; McCaughan F; Weber F; Kouzarides T Sci Adv 2021[Jun]; 7 (27): ä PMID34193418show ga The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates the rapid development of new therapies against coronavirus disease 2019 (COVID-19) infection. Here, we present the identification of 200 approved drugs, appropriate for repurposing against COVID-19. We constructed a SARS-CoV-2-induced protein network, based on disease signatures defined by COVID-19 multiomics datasets, and cross-examined these pathways against approved drugs. This analysis identified 200 drugs predicted to target SARS-CoV-2-induced pathways, 40 of which are already in COVID-19 clinical trials, testifying to the validity of the approach. Using artificial neural network analysis, we classified these 200 drugs into nine distinct pathways, within two overarching mechanisms of action (MoAs): viral replication (126) and immune response (74). Two drugs (proguanil and sulfasalazine) implicated in viral replication were shown to inhibit replication in cell assays. This unbiased and validated analysis opens new avenues for the rapid repurposing of approved drugs into clinical trials. |*Drug Repositioning[MESH] |Antiviral Agents/metabolism/pharmacology/therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/pathology/virology[MESH] |Humans[MESH] |Neural Networks, Computer[MESH] |Proguanil/pharmacology/therapeutic use[MESH] |SARS-CoV-2/immunology/isolation & purification/*physiology[MESH] |Sulfasalazine/pharmacology[MESH]Identification of SARS-CoV-2-induced pathways reveals drug repurposing(epmc).pdf DeepDyve Pubget Overpricing